Yutaka Yasunaga

Summary

Affiliation: Osaka National Hospital
Country: Japan

Publications

  1. doi request reprint Poorly differentiated neuroendocrine carcinoma of the seminal vesicle
    Yutaka Yasunaga
    Department of Urology, National Hospital Organization Osaka National Hospital, Osaka, Japan
    Int J Urol 19:370-2. 2012
  2. doi request reprint Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma
    Atsunari Kawashima
    Department of Urology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita City, Osaka, 565 0871, Japan
    Med Oncol 29:3298-305. 2012
  3. ncbi request reprint [Validation of 2009 TNM classification based on a prognostic analysis of 350 patients treated for renal cell carcinoma]
    Yutaka Yasunaga
    Department of Urology, National Hospital Organization Osaka National Hospital
    Nihon Hinyokika Gakkai Zasshi 103:540-7. 2012
  4. ncbi request reprint [Solitary fibrous tumor of the urinary bladder: a case report]
    Cong Wang
    Department of Urology, National Hospital Organization Osaka National Hospital
    Nihon Hinyokika Gakkai Zasshi 103:640-3. 2012
  5. doi request reprint Seminal vesicle metastasis of renal cell carcinoma
    Kyosuke Matsuzaki
    Department of Urology, National Hospital Organization Osaka Medical Center, Osaka, Japan
    Urology 74:1017-8. 2009
  6. doi request reprint One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients
    Atsunari Kawashima
    Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan
    Eur J Cancer 47:1521-6. 2011

Collaborators

Detail Information

Publications6

  1. doi request reprint Poorly differentiated neuroendocrine carcinoma of the seminal vesicle
    Yutaka Yasunaga
    Department of Urology, National Hospital Organization Osaka National Hospital, Osaka, Japan
    Int J Urol 19:370-2. 2012
    ..The previously biopsied bone tumor was finally diagnosed as a metastasis. A systemic chemotherapy using etoposide and cisplatin failed. The patient died of cancer one-and-a-half years later...
  2. doi request reprint Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma
    Atsunari Kawashima
    Department of Urology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita City, Osaka, 565 0871, Japan
    Med Oncol 29:3298-305. 2012
    ..Continuing therapy for more than one course and maintaining more than 60 % of 1-month relative dose intensity were very important in the prolongation of progression-free survival time regardless of the initial treatment doses...
  3. ncbi request reprint [Validation of 2009 TNM classification based on a prognostic analysis of 350 patients treated for renal cell carcinoma]
    Yutaka Yasunaga
    Department of Urology, National Hospital Organization Osaka National Hospital
    Nihon Hinyokika Gakkai Zasshi 103:540-7. 2012
    ..To validate 2009 TNM classification (7th edition) of renal cell carcinoma (RCC), we reevaluated our RCC database depends on 6th and 7th TNM staging and analyzed a prognostic divergence between subgroups...
  4. ncbi request reprint [Solitary fibrous tumor of the urinary bladder: a case report]
    Cong Wang
    Department of Urology, National Hospital Organization Osaka National Hospital
    Nihon Hinyokika Gakkai Zasshi 103:640-3. 2012
    ..MIB-1 index indicated less than 3%, thus the tumor was diagnosed as a solitary fibrous tumor. The patient has no evidence of disease 16 months after the surgery. The current case was the first report in Japan and the twelfth worldwide...
  5. doi request reprint Seminal vesicle metastasis of renal cell carcinoma
    Kyosuke Matsuzaki
    Department of Urology, National Hospital Organization Osaka Medical Center, Osaka, Japan
    Urology 74:1017-8. 2009
    ..Vesiclectomy was performed. Pathohistologic examination confirmed a metastatic renal cell carcinoma of the seminal vesicle...
  6. doi request reprint One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients
    Atsunari Kawashima
    Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan
    Eur J Cancer 47:1521-6. 2011
    ..We examined the correlation between relative dose intensity (RDI) and clinical outcome of sorafenib therapy in a multi-institutional study...